The FDA ( Food and Drug Administration ) has informed patients and health care professionals that the sponsor of Zelnorm ( Tegaserod ), Novartis Pharmaceuticals, has agreed to stop selling Zelnorm.
Zelnorm is being taken off the market because a new safety analysis has found a higher chance of myocardial infarction, stroke, and worsening heart chest pain that can become a myocardial infarction in patients treated with Zelnorm compared to those treated with placebo.
